[
    [
        {
            "time": "2018-01-02",
            "original_text": "FDA Prolongs Review Date for AbbVie Endometriosis Candidate",
            "features": {
                "keywords": [
                    "FDA",
                    "Prolongs",
                    "Review",
                    "AbbVie",
                    "Endometriosis"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FDA Prolongs Review Date for AbbVie Endometriosis Candidate",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-03",
            "original_text": "Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis",
            "features": {
                "keywords": [
                    "Biotech",
                    "Spectrum",
                    "Incyte",
                    "AveXis",
                    "Novartis",
                    "Merge"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-12",
            "original_text": "Ex-Dividend Alert: Boosted its Dividend by Whopping 35%; Will Trade Ex-Dividend on April 12, 2018",
            "features": {
                "keywords": [
                    "Ex-Dividend",
                    "Boosted",
                    "Dividend",
                    "Whopping",
                    "35%"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Ex-Dividend Alert: Boosted its Dividend by Whopping 35%; Will Trade Ex-Dividend on April 12, 2018",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-04-15",
            "original_text": "A Look at Eli Lilly’s 1Q18 Stock Performance",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "1Q18",
                    "Stock",
                    "Performance"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A Look at Eli Lilly’s 1Q18 Stock Performance",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-04-16",
            "original_text": "Is Gilead Sciences, Inc. (GILD) a Buy?",
            "features": {
                "keywords": [
                    "Gilead Sciences",
                    "Buy"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Is Gilead Sciences, Inc. (GILD) a Buy?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-04-17",
            "original_text": "AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch",
            "features": {
                "keywords": [
                    "AGTC",
                    "Gene Therapy",
                    "FDA",
                    "Delays",
                    "Decision",
                    "Elagolix",
                    "KPTI"
                ],
                "sentiment_score": -0.4,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AGTC Awaits Gene Therapy Data, FDA Delays Decision On Elagolix, KPTI On Watch",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]